Summary of Cytek Biosciences (CTKB) Conference Call Industry Overview - The conference focused on advancements in proteomics and cellular research, highlighting the importance of new technologies in these fields [2][3]. Key Companies Discussed - **Cytek Biosciences**: A life science tool company specializing in flow cytometry technology [6]. - **Quantum SI**: A company offering next-generation protein sequencing technology [3]. Core Points and Arguments Technological Advancements - **Quantum SI's Technology**: Introduces next-generation protein sequencing that allows for the study of single amino acid variants and post-translational modifications, which are crucial for understanding disease progression and therapy responses [3][4]. - **Cytek's Full Spectrum Technology**: Enhances flow cytometry by capturing all signals from cells, allowing for the detection of more parameters and improving sensitivity, particularly in cancer studies [6][7][8]. Market Dynamics - **Demand for New Applications**: Both companies noted a shift in customer needs towards more complex studies that traditional technologies could not address [4][5]. - **Challenges in Adoption**: New technologies face skepticism regarding their accuracy and applicability, necessitating proof of concept through data generation in leading research centers [10][11]. Business Management in a Challenging Market - **Financial Resilience**: Quantum SI highlighted its strong balance sheet, allowing it to maintain strategic investments despite market challenges [16][18]. - **Flow Cytometry Market**: Cytek emphasized the ongoing need for flow cytometers in labs, with many existing units nearing replacement, presenting an opportunity for growth [19][20][21]. Replacement Opportunities - **Market Size**: There are approximately 50,000 flow cytometers in use, with many due for replacement, creating a significant market opportunity [22]. - **Key Factors for Replacement**: New technology performance, backward compatibility, and overall cost reduction are critical for capturing replacement opportunities [23][24]. Clinical Market Progress - **Geographic Expansion**: Cytek has received clinical approvals in China and is progressing in Europe, with plans to navigate the more complex FDA approval process in the U.S. [27][28][29]. Future Pipeline and Innovations - **Quantum SI's Proteus Platform**: Expected to launch in 2026, this platform will significantly enhance sequencing capabilities, allowing for more complex sample analysis [36][39]. - **AI Integration**: Both companies are leveraging AI to improve operational efficiency and enhance product capabilities, with Quantum SI focusing on proprietary data to train AI models for better performance [40][41][45]. Additional Important Insights - **Market Disruption**: Cytek views competition as an opportunity to solidify its market leadership, especially in light of disruptions from competitors [25][26]. - **Revenue Growth**: Cytek's revenue growth has outpaced instrument sales, indicating a strong service and reagent business [26]. This summary encapsulates the key discussions and insights from the conference, highlighting the advancements in proteomics and flow cytometry, market dynamics, and future opportunities for both Cytek Biosciences and Quantum SI.

Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +150.00%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.09, delivering a surprise of -125%.Over the last four quarters, ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $45.6 million, a decrease of $1 million or 2.2% compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC, partially offset by strong growth in service revenue worldwide, which grew by 18% [8][22] - Product revenue decreased by 9% year-over-year, driven by a significant decline in EMEA, while US product revenue increased by 2% [22][23] - GAAP gross profit was $23.9 million, a 6% decline versus the prior year, with a gross profit margin of 52% compared to 55% in the prior year quarter [25] Business Line Data and Key Metrics Changes - Recurring revenue businesses reached 32% of trailing twelve-month sales in Q2, growing by 16% year-over-year, with service and reagent revenue each increasing by 18% [9][10] - FSP unit volume grew by 3% in Q2, led by AURORA analyzers, with particular strength in the US showing 10% year-over-year growth [10][11] - Service revenue continued to deliver strong growth of 18% in Q2 versus the prior year and 21% for the first half [24] Market Data and Key Metrics Changes - Total US revenue was up 7% over the prior year, driven by service and reagents, while EMEA revenue declined by 11% due to lower instrument sales [11][24] - APAC sales declined following a strong Q1, primarily due to longer sales cycles, but showed solid growth on a year-over-year basis [12] - The rest of the world region, including Canada and Latin America, delivered single-digit percentage revenue growth compared to last year's second quarter [12] Company Strategy and Development Direction - The company aims to solidify its market leadership in next-gen cell analysis solutions through innovation and differentiated offerings, including the launch of the Cytec Aurora EVO system [17][31] - The focus remains on expanding the installed base globally, which is expected to drive growth in instrument revenue and sustainable recurring revenue in service and reagent businesses [31][32] - The company is open to M&A opportunities that have synergy potential, while also investing in organic growth through its reagent and service segments [48][50] Management's Comments on Operating Environment and Future Outlook - Management noted that the capital equipment spending environment remains challenging, particularly in the academic and government sectors, but expects a recovery over time [14][32] - The company narrowed its full-year 2025 revenue guidance to a range of $196 million to $205 million, reflecting overall growth of -2% to +2% compared to 2024 [29] - Management expressed confidence in the growth of recurring revenue streams and the core business despite the current market challenges [29][30] Other Important Information - The installed instrument base grew by 146 units in Q2, bringing the total to 3,295 units, indicating steady expansion across a diverse customer base [15][16] - The company reported a positive free cash flow of $900,000 in Q2, despite stock repurchases totaling $4.5 million [28] Q&A Session Summary Question: How is the Flow Cytometry market performing and are there any competitive concerns? - Management indicated that the overall flow cytometry market is experiencing a downturn due to funding challenges, but the company continues to grow its core business and unit volume [34][35] Question: How comfortable is the company with the second half guidance? - Management expects stronger performance in the second half, driven by recurring revenue growth, while capital spending is anticipated to be back-end weighted [40][41] Question: Is the company open to M&A opportunities? - Management confirmed openness to M&A, focusing on opportunities with synergy potential in existing markets or adjacencies [48][49] Question: What is the expected contribution from new products like AURORA EVO? - AURORA EVO is expected to be a significant contributor to revenue, supporting margins, while MUSE Micro is not expected to have a major impact on margins [64][65] Question: What are the drivers of service revenue growth? - Service revenue growth is driven by the installed base, with expectations that this growth will continue based on past performance [66][67]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 ...

Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2025 Financial Results FREMONT, Calif., August 6, 2025 (GLOBE NEWSWIRE) – Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights "The progress we achieved in the first half of this year is underscored by steady growth in our FSP unit placements, and in our recurring revenue businesses, despit ...

FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024Expanded to a total installed base of 3,295 Cytek instruments, adding 146 units in the second quarter of 2025, a ...

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].

Financial Performance & Outlook - Cytek's 2024 revenue reached $200.5 million, a 4% year-over-year increase[14] - Adjusted EBITDA for 2024 was $22.4 million, representing a 77% year-over-year growth[14] - The company anticipates revenue between $204 million and $212 million for 2025[11] - Cytek has authorized a $50 million share repurchase program[11] Market Position & Growth - Cytek has placed 3,034 units of its instruments[8] - The company has a broad customer base of approximately 2,000 customers across 70+ countries[8] - The initial total addressable market (TAM) for cell analysis in 2025 is estimated at $7.5 billion[20] - The adjacent TAM is estimated at $8.5 billion[20] Product & Technology - Cytek's FSP (Full Spectrum Profiling) technology underpins its core instruments[28] - Amnis ImageStream revenue experienced 14% growth in 2024[32] - The company's cloud-based operating system has over 16,000 users, with a user base growth of over 160% in 2024[42]

Summary of Cytek Biosciences (CTKB) FY Conference Call - June 11, 2025 Company Overview - **Company**: Cytek Biosciences (CTKB) - **Industry**: Biotechnology, specifically in flow cytometry and related services Key Points and Arguments Business Segmentation and Performance - The business is divided into two main segments: service and instrument sales, with service showing consistent growth linked to the installed base of instruments [3][4][22] - The reagent business has shown steady growth, with improvements in execution and delivery times contributing to confidence in future performance [4][22] - The Asia Pacific and rest of the world markets are experiencing good growth, contrasting with pressures on academic funding in the U.S. and Europe [5][6][32] Market Conditions and Guidance - Guidance for the year is bracketed between a decline of 2% and growth of 5%, reflecting uncertainty in academic funding and purchasing decisions [6][7] - The flow cytometry market overall saw a decline of 2% in Q1, with Cytek outperforming this due to a growing installed base and product innovation [10][12][13] - The company expects to continue outpacing the market due to its focus on full spectrum profiling and strong product offerings [14] Service Business Growth - The service business is projected to grow faster than instrument sales, potentially becoming a larger portion of overall revenue [22][23] - Recurring revenue, including services and reagents, currently accounts for about 31% of total revenue, with aspirations to increase this to the 40% range in the future [22][30] Regional Insights - Cytek has established a strong presence in China, benefiting from government stimulus programs and becoming a recognized brand in the market [32][33] - The company ranks as the third supplier in China, indicating significant growth potential in this region [32] Cost Structure and Profitability - Approximately 75% to 80% of incremental revenue contributes to EBITDA, with gross margins expected to improve from 55% towards 60% [38][40] - The company has a fixed versus variable cost structure that allows for significant margin expansion as revenue grows [39][42] Technological Advancements - The Cytek Cloud platform has gained traction with 18,000 users, enhancing customer engagement and providing a competitive edge through data management and analysis capabilities [43][44][48] - The platform allows for efficient panel design and reagent purchasing, which is expected to drive service revenue growth [44][48] Investor Insights - The company emphasizes its positive EBITDA and cash flow generation, distinguishing itself from other small-cap tools companies [50] - Recent product innovations, such as the new AURORA analyzer, have received positive feedback, suggesting strong future sales potential [50][51] Additional Important Content - The company is managing tariff impacts through regional manufacturing strategies, with minimal expected effects on gross margins [34][36] - The service contracts are crucial for maintaining high instrument utilization, which is essential for core labs operating as businesses [23][26]

Improved Sample Throughput, Automation Capabilities and Updated Hardware Design Cytek Aurora™ Evo Cytek today unveiled the Cytek Aurora™ Evo system, a full spectrum flow cytometer that builds on the trusted performance of the Cytek Aurora system. Designed to set a new standard in spectral flow cytometry, the Cytek Aurora Evo flow cytometer maintains the reproducibility researchers rely on, now with added high-throughput performance and automation capabilities. FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIR ...